{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T00:23:29Z","timestamp":1792887809099,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T00:00:00Z","timestamp":1692576000000},"content-version":"vor","delay-in-days":538,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s13311-022-01200-3","type":"journal-article","created":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T15:06:39Z","timestamp":1645110399000},"page":"464-475","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Nusinersen in Adults with 5q Spinal Muscular Atrophy: a Systematic Review and Meta-analysis"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1958-0063","authenticated-orcid":false,"given":"Maria","family":"Gavriilaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Moschou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasileios","family":"Papaliagkas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Notas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelia","family":"Chatzikyriakou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotirios","family":"Papagiannopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianthi","family":"Arnaoutoglou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasilios K.","family":"Kimiskidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9630","key":"10.1007\/s13311-022-01200-3_bib1","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1016\/S0140-6736(08)60921-6","article-title":"Spinal muscular atrophy","volume":"371","author":"Lunn","year":"2008","journal-title":"Lancet"},{"issue":"1","key":"10.1007\/s13311-022-01200-3_bib2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/ejhg.2011.134","article-title":"Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72,400 specimens","volume":"20","author":"Sugarman","year":"2012","journal-title":"Eur J Hum Genet"},{"issue":"2","key":"10.1007\/s13311-022-01200-3_bib3","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","article-title":"Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care","volume":"28","author":"Mercuri","year":"2018","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"10.1007\/s13311-022-01200-3_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pediatrneurol.2011.09.001","article-title":"Spinal muscular atrophy: a clinical and research update","volume":"46","author":"Markowitz","year":"2012","journal-title":"Pediatr Neurol"},{"issue":"2","key":"10.1007\/s13311-022-01200-3_bib5","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1086\/338627","article-title":"Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy","volume":"70","author":"Feldkotter","year":"2002","journal-title":"Am J Hum Genet"},{"issue":"10063","key":"10.1007\/s13311-022-01200-3_bib6","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","article-title":"Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study","volume":"388","author":"Finkel","year":"2016","journal-title":"Lancet (London, England)"},{"issue":"4","key":"10.1007\/s13311-022-01200-3_bib7","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1128\/MCB.26.4.1333-1346.2006","article-title":"Splicing of a critical exon of human survival motor neuron is regulated by a unique silencer element located in the last intron","volume":"26","author":"Singh","year":"2006","journal-title":"Mol Cell Biol"},{"issue":"7","key":"10.1007\/s13311-022-01200-3_bib8","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus sham control in later-onset spinal muscular atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1007\/s13311-022-01200-3_bib9","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1007\/s13311-022-01200-3_bib10","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/ene.13534","article-title":"Muscle strength and motor function throughout life in a cross-sectional cohort of 180 patients with spinal muscular atrophy types 1c\u20134","volume":"25","author":"Wadman","year":"2018","journal-title":"Eur J Neurol"},{"issue":"3","key":"10.1007\/s13311-022-01200-3_bib11","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/acn3.51276","article-title":"Type I SMA \u201cnew natural history\u201d: long-term data in nusinersen-treated patients","volume":"8","author":"Pane","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"10.1007\/s13311-022-01200-3_bib12","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13023-021-01695-7","article-title":"Systematic literature review of the economic burden of spinal muscular atrophy and economic evaluations of treatments","volume":"16","author":"Dangouloff","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"10.1007\/s13311-022-01200-3_bib13","doi-asserted-by":"crossref","unstructured":"Gavriilaki M, Kimiskidis VK, Gavriilaki E. Precision medicine in neurology: the inspirational paradigm of complement therapeutics. Pharmaceuticals. 2020;13(11).","DOI":"10.3390\/ph13110341"},{"key":"10.1007\/s13311-022-01200-3_bib14","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"4","key":"10.1007\/s13311-022-01200-3_bib15","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/mus.26419","article-title":"Revised upper limb module for spinal muscular atrophy: 12 month changes","volume":"59","author":"Pera","year":"2019","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1007\/s13311-022-01200-3_bib16","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12883-017-0790-9","article-title":"Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy","volume":"17","author":"Pera","year":"2017","journal-title":"BMC Neurol"},{"issue":"8","key":"10.1007\/s13311-022-01200-3_bib17","doi-asserted-by":"crossref","first-page":"e12140","DOI":"10.1371\/journal.pone.0012140","article-title":"SMA CARNI-VAL trial part I: double-blind, randomized, placebo-controlled trial of L-carnitine and valproic acid in spinal muscular atrophy","volume":"5","author":"Swoboda","year":"2010","journal-title":"PLoS ONE"},{"issue":"5","key":"10.1007\/s13311-022-01200-3_bib18","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1002\/mus.25120","article-title":"Six-minute walk test is reliable and valid in spinal muscular atrophy","volume":"54","author":"Dunaway Young","year":"2016","journal-title":"Muscle Nerve"},{"issue":"4","key":"10.1007\/s13311-022-01200-3_bib19","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1214\/aoms\/1177729756","article-title":"Transformations related to the angular and the square root","volume":"21","author":"Freeman","year":"1950","journal-title":"Ann Math Stat"},{"key":"10.1007\/s13311-022-01200-3_bib20","unstructured":"Higgins J, Green S. Identifying and measuring heterogeneity. Cochrane handbook for systematic reviews of interventions version. 2011;510."},{"key":"10.1007\/s13311-022-01200-3_bib21","doi-asserted-by":"crossref","unstructured":"De Wel B, Goosens V, Sobota A, Van Camp E, Geukens E, Van Kerschaver G, et al. Nusinersen treatment significantly improves hand grip strength, hand motor function and MRC sum scores in adult patients with spinal muscular atrophy types 3 and 4. 2020.","DOI":"10.1007\/s00415-020-10223-9"},{"issue":"4","key":"10.1007\/s13311-022-01200-3_bib22","doi-asserted-by":"crossref","first-page":"e413","DOI":"10.1212\/WNL.0000000000009914","article-title":"Nusinersen in adult patients with spinal muscular atrophy: observations from a single center","volume":"95","author":"Moshe-Lilie","year":"2020","journal-title":"Neurology"},{"issue":"4","key":"10.1007\/s13311-022-01200-3_bib23","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1474-4422(20)30037-5","article-title":"Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study","volume":"19","author":"Hagenacker","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-022-01200-3_bib24","unstructured":"Maggi L, Bello L. Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3. 2020."},{"issue":"4","key":"10.1007\/s13311-022-01200-3_bib25","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3233\/JND-190416","article-title":"Safety and treatment effects of nusinersen in longstanding adult 5q-SMA type 3 - a prospective observational study","volume":"6","author":"Walter","year":"2019","journal-title":"J Neuromuscul Dis"},{"key":"10.1007\/s13311-022-01200-3_bib26","doi-asserted-by":"crossref","unstructured":"Freigang M, Wurster CD, Hagenacker T, Stolte B, Weiler M, Kamm C, et al. Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatment. Ann Clin Transl Neurol. 2021.","DOI":"10.1002\/acn3.51340"},{"issue":"3","key":"10.1007\/s13311-022-01200-3_bib27","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3233\/JND-190453","article-title":"Prospective cohort study of nusinersen treatment in adults with spinal muscular atrophy","volume":"7","author":"Yeo","year":"2020","journal-title":"J Neuromuscul Dis"},{"issue":"2","key":"10.1007\/s13311-022-01200-3_bib28","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/mus.26769","article-title":"Nusinersen for older patients with spinal muscular atrophy: a real-world clinical setting experience","volume":"61","author":"Veerapandiyan","year":"2020","journal-title":"Muscle Nerve"},{"key":"10.1007\/s13311-022-01200-3_bib29","first-page":"625","article-title":"The effect and challenges of nusinersen treatment in adult spinal muscular atrophy patients-preliminary results","volume":"27","author":"Inan","year":"2020","journal-title":"Eur J Neurol"},{"key":"10.1007\/s13311-022-01200-3_bib30","doi-asserted-by":"crossref","unstructured":"Jochmann E, Steinbach R, Jochmann T, Chung HY, R\u00f6diger A, Neumann R, et al. Experiences from treating seven adult 5q spinal muscular atrophy patients with nusinersen. Ther Adv Neurol Disord. 2020;13.","DOI":"10.1177\/1756286420907803"},{"issue":"5","key":"10.1007\/s13311-022-01200-3_bib31","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1111\/jcmm.14939","article-title":"Nusinersen treatment and cerebrospinal fluid neurofilaments: an explorative study on spinal muscular atrophy type 3 patients","volume":"24","author":"Faravelli","year":"2020","journal-title":"J Cell Mol Med"},{"key":"10.1007\/s13311-022-01200-3_bib32","first-page":"948","article-title":"Longer-term experience with nusinersen in teenagers and young adults with spinal muscular atrophy: phosphorylated neurofilament heavy chain (pNF-H) and efficacy results from the CS2-12\/SHINE studies","volume":"27","author":"Muntoni","year":"2020","journal-title":"Eur J Neurol"},{"key":"10.1007\/s13311-022-01200-3_bib33","doi-asserted-by":"crossref","unstructured":"Yeo CJJ, Simeone S, Zhang RZ, Trautman K, Damron B, Nwe P, et al. Outcome measures for nusinersen efficacy in adults with spinal muscular atrophy. Neurology. 2019;92(15).","DOI":"10.1212\/WNL.92.15_supplement.S5.008"},{"issue":"7650","key":"10.1007\/s13311-022-01200-3_bib34","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"7","key":"10.1007\/s13311-022-01200-3_bib35","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/S1474-4422(20)30183-6","article-title":"Natural history data in adults with SMA","volume":"19","author":"Vazquez-Costa","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-022-01200-3_bib36","doi-asserted-by":"crossref","unstructured":"Gavriilaki M, Moschou M, Papaliagkas V, Notas K, Chatzikyriakou E, Zafeiridou G, et al. Biomarkers of disease progression in adolescents and adults with 5q spinal muscular atrophy: a systematic review and meta-analysis. Neuromuscul Disord. 2022.","DOI":"10.1016\/j.nmd.2021.12.005"},{"key":"10.1007\/s13311-022-01200-3_bib37","doi-asserted-by":"crossref","unstructured":"V\u00e1zquez-Costa JF, Herv\u00e1s D. Minimal detectable change and minimal clinically important difference in spinal muscular atrophy patients. Eur J Neurol. 2021.","DOI":"10.1111\/ene.14780"},{"issue":"14","key":"10.1007\/s13311-022-01200-3_bib38","doi-asserted-by":"crossref","first-page":"e1988","DOI":"10.1212\/WNL.0000000000010540","article-title":"Muscle strength and motor function in adolescents and adults with spinal muscular atrophy","volume":"95","author":"Wijngaarde","year":"2020","journal-title":"Neurology"},{"issue":"6","key":"10.1007\/s13311-022-01200-3_bib39","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1002\/ana.25900","article-title":"Clinical variability in spinal muscular atrophy type III","volume":"88","author":"Coratti","year":"2020","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-022-01200-3_bib40","unstructured":"Biogen. Study of nusinersen (BIIB058) in participants with spinal muscular atrophy (DEVOTE) Clinicaltrials.gov [cited 2021 13\/5\/2021]. NCT04089566].\u00a02019. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04089566."}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-022-01200-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13311-022-01200-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923000661?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923000661?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-022-01200-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:33:14Z","timestamp":1761805994000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923000661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S1878747923000661"],"URL":"https:\/\/doi.org\/10.1007\/s13311-022-01200-3","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nusinersen in Adults with 5q Spinal Muscular Atrophy: a Systematic Review and Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-022-01200-3","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}